



MARKER
Therapeutics

Non-Clinical Data Supporting the MT-401 Off-the-Shelf Program

MT-401 OTS showed anti-tumor
activity in AML cells

August 7, 2023

Forward Looking Statements

Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions, including without limitation statements regarding Market Therapeutics, Inc.’s (“Marker” or the “Company”) intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the Company’s research, development and regulatory activities and expectations relating to its non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct and success of the Company’s clinical trials of its product candidates, including MT-401 Off-the-Shelf (“OTS”) for the treatment of patients with Acute Myeloid Leukemia (“AML”). Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principals, partners, subsidiaries or affiliates, or any of such person’s board members, officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. Certain information set forth herein includes estimates, projections and targets and involves significant elements of subjective judgement and analysis, which may or may not be correct. No representations are made as to the accuracy of such estimates, projections or targets or that all assumptions relating to such estimates, projections or targets have been considered or stated or that such estimates, projections or targets will be realized. This presentation does not purport to contain all of the information that may be required to evaluate the Company and any recipient hereof should conduct its own independent analysis of the Company and the data and information contained herein. Any forward-looking statements are not guarantees of future performance and actual results may differ materially from estimates in the forward-looking statements. Unless otherwise stated, all information in this presentation is as of the date of the cover page of this presentation, and the Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Partially HLA-matched MT-401 Off-the-Shelf (OTS) product demonstrated *in vitro* anti-tumor activity in a long-term leukemia cell line model. THP-1, an acute monocytic leukemia cell line, was used to demonstrate *in vitro* efficacy of allogeneic MT-401 in an OTS setting (MT-401 OTS). MT-401 was manufactured from three healthy donors with only partial human leukocyte antigen (HLA) matching (2 out of 8 HLA alleles) to the THP-1 leukemic cell line. Despite only a partial HLA match, MT-401 OTS was able to kill leukemia cells (**Panel A**). Bioluminescent images of leukemic cell growth from day 1 (Day of MT-401 infusion) and day 5 (4 days after MT-401 infusion) are shown in **Panel B**. In sum, MT-401 OTS reversed cancer cell growth and eliminated cancer cells by day 5. These data provide non-clinical support for the use of a partially matched MT-401 OTS product as a treatment for patients with leukemia.

